Founder & CEO

Brad is Delve Bio’s CEO and co-founder. Most recently, Brad was a senior associate at Xontogeny, where he made seed and series A investments across the life sciences. Previously, Brad was a computational biologist at Intellia Therapeutics applying his expertise to CRISPR/CAS9 therapeutics. Prior to Intellia, Brad was a computational associate at The Broad Institute where he developed algorithms for the analysis of cancer genome sequencing data. Brad holds a BS in Biology and Economics from Georgetown University and an MBA in finance and entrepreneurship from Boston College. In his free time, Brad enjoys making homemade pasta and rooting for the San Francisco 49ers and his beloved Georgetown Hoyas.

Head of R&D

Emily is an expert in Next Generation Sequencing technologies and their application to pathogen detection. She previously led a research group at the Chan Zuckerberg Biohub focused on novel CRISPR/Cas-based methods for enhancing sequencing readouts. In 2020, Emily led the Biohub’s efforts to partner with the UCSF and create an expansion lab for COVID-19 PCR testing, where her team processed more than 160,000 PCR tests on behalf of public health departments and clinical research studies. In 2021 and 2022, Emily worked as a Scientist in Residence at venture foundry firm The Production Board. Emily completed her PhD in Jim Wells’ lab at UCSF in 2012. She was born and raised in Cambridge, MA but has called San Francisco home for over 17 years.

Chief Medical Officer

Steve is a board-certified clinical pathologist with expertise in microbiology and infectious disease diagnostics. He spent over 15 years as Director of the Microbiology Laboratory at UCSF, where he specialized in development and validation of molecular diagnostic testing for pathogen detection and characterization and pioneered the implementation of metagenomic next-generation sequencing in the clinical laboratory. Prior to joining Delve, he was Senior Director in Medical Affairs for Global Infectious Disease at Illumina, providing guidance on clinical utility and product development for sequencing-based microbial analysis tools. At Delve, he aims to improve access to mNGS testing for diagnosis of infections and demonstrate how this novel technology can improve patient care. He also enjoys hiking, biking, surfing and spending time with his family in the Bay Area.

Chief Commercial Officer

Jeff is an entrepreneurial business leader with broad commercialization experience in both start-ups (8 times) and large multi-national Fortune 100 companies, and he has considerable experience launching & commercializing disruptive healthcare technologies. Prior to joining Delve, he spent the last 7-years commercializing NGS-based technologies in microbiology and infectious diseases as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina). Jeff also served as Chief Commercial Officer at GenePeeks, where he launched a disruptive NGS-based technology platform for rare autosomal recessive genetic diseases. In addition, Jeff also played a key role at Foundation Medicine (acquired by Roche) where he served as the Vice President of Sales and Client Services, commercializing its comprehensive tumor genomic profiling NGS-assays for cancer patients. Before joining Foundation Medicine, Jeff held several executive level positions at Caris Life Sciences commercializing NGS-based assays for cancer. Last, Jeff has also helped build several other high-growth companies, including the start-up Astra Merck (now AstraZeneca) and AdvancePCS (now CVS Health). Jeff holds a Bachelor of Science (B.S.) in Chemistry from Merrimack College, a Master’s of Science (M.S.) in Organic/Medicinal Chemistry from Boston College, and a Master’s in Business Administration (MBA) from Rollins College. Jeff has six (6) adopted daughters from China and enjoys exercising and cooking with his children. In his spare time, Jeff is the Founder of a private 501(c)(3) nonprofit foundation dedicated to supporting research and families with children with rare cancers, rare genetic diseases, and rare congenital heart disease.

VP of Product Development and Leadership

Coren is an experienced leader in molecular diagnostic test development. Most recently Coren was the Senior Director and Lifecycle Lead for Companion Diagnostics at TenSixteen Bio, and previously served as the Head of Lab Operations at SeQure Dx. Prior to that, Coren spent several years engaged in and leading development and validation activities for companion diagnostic NGS-based oncology assays at Foundation Medicine, supporting many PMA and sPMA initiatives. In her free time, Coren enjoys refinishing mid-century modern furniture and roasting coffee.  

Director of Software Engineering

Andrew has a proven track record of implementing innovative laboratory software solutions for over a decade. Previously, at Intellia Therapeutics, he managed a team of developers and created a custom LIMS to bridge the gap between abstract genomic data with the physical R&D laboratory. Prior to that, at HealthEdge, he gained perspective on how to develop large enterprise-grade software. At Foundation Medicine, Andrew augmented an off-the-shelf LIMS to carefully track patient samples through the regulated laboratory. Starting off his career at HighRes Biosolutions, he led the team that commissioned automating systems and developed LIMS integrations for biotech across the US. Andrew has a BS in Computer Science from Framingham State University. At home Andrew spends his time tinkering with technology and raising two daughters.

Senior Director of Marketing and Business Development

Amy is Delve Bio’s Senior Director of Marketing and Business Development. She has held roles that have spanned R&D, product management, and marketing. Amy has launched and managed multiple clinical diagnostic products worldwide, including in sub-Saharan Africa, where she directly witnessed the impact of diagnostics on an HIV-patient’s life – a single test granted access to life-saving treatment. She holds a PhD in Biophysics from Harvard University, and a BS in Bioengineering from UC Berkeley. When not being bossed around by her toddler, Amy can be found outdoors, whether it’s climbing, biking, or tending to her large garden.

Head of Bioinformatics

Brian earned his PhD in the DeRisi lab at UCSF where he contributed to the genesis of Delve’s core metagenomic technology while serving on the precision medicine neuroinflammation board. He brings a decade of clinical assay development and bioinformatics experience to Delve, having previously led teams pioneering liquid biopsy and cancer biomarker discovery technologies at Freenome, standing up AAV gene therapy QA/QC and clinical trial data pipelines at Audentes Therapeutics, and completing multiple consulting engagements with early stage biotech companies. Outside of work, you will likely find Brian camping and fishing with his wife and daughter in the forests surrounding his home in Spokane, Washington.